ArticleTherapeutic advances in urology
Diagnostic performance of apparent diffusion coefficients for prostate cancer in patients with PI-RADS 4-5 lesions: a retrospective analysis.
Article in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quantitative assessment of prostate cancer using an individualized apparent diffusion coefficient intensity scale: a proposal.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While prostate biopsy is the standard diagnostic approach for Prostate Imaging-Reporting and Data System (PI-RADS) 4-5 lesions, some of these biopsies yield negative results. Objective: To determine the optimal minimum apparent diffusion coefficient (ADCmin) and prostate-specific antigen density (PSAD) threshold and develop a quantitative diagnostic standard that would enhance the diagnostic accuracy. Design and methods: The study included 361 patients who met the criteria and had undergone prostate biopsy between January 2021 and December 2024. Comprehensive clinical information was collected. Following the standardization of the region of interest protocol, apparent diffusion coefficient was measured for all PI-RADS 4-5 lesions. Univariate and multivariate logistic regression analyses were employed to identify independent predictors, and diagnostic efficacy was assessed using receiver operating characteristic curves and the area under the curve (AUC). Results: Of the 361 patients, 252 (69.8%) were diagnosed with clinically significant prostate cancer (csPCa), and 109 (30.2%) were diagnosed with clinically insignificant prostate cancer and non-prostate cancer. Multivariate analysis revealed PSAD and ADCmin to be independent predictors of csPCa. The AUC values of PSAD and ADCmin for diagnosing csPCa were 0.797 (95% CI: 0.751-0.837) and 0.777 (95% CI: 0.731-0.819), respectively. Applying the criterion of "PSAD ⩾ 0.35 ng/mL Conclusion: The results demonstrate that the ADCmin exhibits high diagnostic accuracy for detecting csPCa in patients with PI-RADS 4-5 lesions. Furthermore, diagnostic criteria were established for patients based on PSAD and ADCmin to aid in clinical decision-making regarding prostate biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.